Clinical Significance of NKD Inhibitor of WNT Signaling Pathway 1 (NKD1) in Glioblastoma

Table 1

Cancer-specific survival analyses.

Variables	Cases (n = 66)	Univariate analysis		Multivariate analysis
		HR (95% CI)	value	HR (95% CI)	value
Age
<40 yo	36	Reference		Reference
≥40 yo	30	4.8 (1.6–15.0)	0.006	6.0 (1.9–19.2)	0.003
Sex
Female	29	Reference
Male	37	1.8 (0.7–4.9)	0.212
GBM site
Parietal lobe	6	Reference		Reference
Temporal lobe	24	0.4 (0.1–1.2)	0.094	0.6 (0.2–2.0)	0.403
Frontal lobe	32	0.2 (0.1–0.6)	0.006	0.2 (0.1–0.7)	0.011
Unspecific	4	0.3 (0.04–2.8)	0.316	0.4 (0.1–3.7)	0.430
GBM size
<2.4 cm	32	Reference
≥2.4 cm	34	0.6 (0.3–1.6)	0.344
Surgery
Local resection	37	Reference
Radical resection	12	0.5 (0.1–4.2)	0.540
Lobectomy	17	0.8 (0.3–2.1)	0.600
NKD1 expression
Low	33	Reference		Reference
High	33	0.3 (0.1–0.9)	0.027	0.3 (0.1–0.8)	0.019

HR: hazard ratio, GBM: glioblastoma, and NKD1: NKD inhibitor of Wnt signaling pathway 1.